Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study of Mosliciguat in PH-ILD

NCT: NCT06635850 · ACTIVE_NOT_RECRUITING

NCT IDNCT06635850
StatusACTIVE_NOT_RECRUITING
Start Date2024-10-29
SponsorPulmovant, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑